These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33428730)

  • 21. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
    Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
    Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis.
    Song YS; Jung CK; Jung KC; Park YJ; Won JK
    J Korean Med Sci; 2017 Oct; 32(10):1721-1726. PubMed ID: 28875621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic landscape of papillary thyroid carcinoma in the Chinese population.
    Liang J; Cai W; Feng D; Teng H; Mao F; Jiang Y; Hu S; Li X; Zhang Y; Liu B; Sun ZS
    J Pathol; 2018 Feb; 244(2):215-226. PubMed ID: 29144541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
    Xu B; Ghossein R
    Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.
    Tiedje V; Ting S; Herold T; Synoracki S; Latteyer S; Moeller LC; Zwanziger D; Stuschke M; Fuehrer D; Schmid KW
    Oncotarget; 2017 Jun; 8(26):42613-42620. PubMed ID: 28489587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
    Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study.
    Deeken-Draisey A; Yang GY; Gao J; Alexiev BA
    Hum Pathol; 2018 Dec; 82():140-148. PubMed ID: 30075157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.
    Gibson WJ; Ruan DT; Paulson VA; Barletta JA; Hanna GJ; Kraft S; Calles A; Nehs MA; Moore FD; Taylor-Weiner A; Wala JA; Zack TI; Lee TC; Fennessy FM; Alexander EK; Thomas T; Janne PA; Garraway LA; Carter SL; Beroukhim R; Lorch JH; Van Allen EM
    Clin Cancer Res; 2017 May; 23(9):2367-2373. PubMed ID: 27797976
    [No Abstract]   [Full Text] [Related]  

  • 31. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.
    Wu H; Sun Y; Ye H; Yang S; Lee SL; de las Morenas A
    Pathol Oncol Res; 2015 Jul; 21(3):695-701. PubMed ID: 25588542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal evolution analysis of paired anaplastic and well-differentiated thyroid carcinomas reveals shared common ancestor.
    Dong W; Nicolson NG; Choi J; Barbieri AL; Kunstman JW; Abou Azar S; Knight J; Bilguvar K; Mane SM; Lifton RP; Korah R; Carling T
    Genes Chromosomes Cancer; 2018 Dec; 57(12):645-652. PubMed ID: 30136351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.
    Khan SA; Ci B; Xie Y; Gerber DE; Beg MS; Sherman SI; Cabanillas ME; Busaidy NL; Burtness BA; Heilmann AM; Bailey M; Ross JS; Sher DJ; Ali SM
    Head Neck; 2019 Jun; 41(6):1928-1934. PubMed ID: 30758123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
    Sykorova V; Dvorakova S; Vcelak J; Vaclavikova E; Halkova T; Kodetova D; Lastuvka P; Betka J; Vlcek P; Reboun M; Katra R; Bendlova B
    Anticancer Res; 2015 Apr; 35(4):2029-36. PubMed ID: 25862857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: A case report with treatment implications and review of literature.
    Torrez M; Braunberger RC; Yilmaz E; Agarwal S
    Pathol Res Pract; 2020 Oct; 216(10):153146. PubMed ID: 32853962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
    McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
    Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
    Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS
    Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three-dimensional genome landscape comprehensively reveals patterns of spatial gene regulation in papillary and anaplastic thyroid cancers: a study using representative cell lines for each cancer type.
    Zhang L; Xu M; Zhang W; Zhu C; Cui Z; Fu H; Ma Y; Huang S; Cui J; Liang S; Huang L; Wang H
    Cell Mol Biol Lett; 2023 Jan; 28(1):1. PubMed ID: 36609218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.